
Algorithm for Hidradenitis Suppurativa (HS)



HS has a high rate of co-morbidities that should be screened for at the time of diagnosis¹ HPI/ROS findings - Ask screening question: Have you had 2 or more outbreaks of boils in the last 6-12 months in the axillae, groin, inframammary folds or buttocks? **Treatment goal:** Reduce scarring and development of new lesions while preventing progression of disease to improve symptoms and quality of life



#	Subject	Description
1	Associated co- morbidities	HS has a very high co-morbidity burden, with newer guidelines recommending that the following systems should be screened for at the time of diagnosis: • Metabolic (obesity, dyslipidemia, hypertension, metabolic syndrome) - Exam: BMI, blood pressure - Labs: fasting lipid panel, hemoglobin A1c, fasting blood glucose • Endocrinologic (diabetes, PCOS, precocious puberty/premature adrenarche) - History: menstrual irregularities - Exam: PCOS screening (signs of hyperandrogenism), signs of precocious puberty - Labs: PCOS screening labs if appropriate • Psychiatric (depression, anxiety, substance use disorder) - History: PHQ-2 and/or PHQ-9, GAD-7, AUDIT-C questionnaire/opioid risk tool • Inflammatory conditions (inflammatory bowel disease, spondyloarthritis) - History: arthritis and inflammatory bowel disease screening questions - Labs: IBD screening labs if appropriate • Dermatologic (acne, pilonidal disease, dissecting cellulitis of scalp, pyoderma gangrenosum) - Exam: Full skin exam Management and referrals to appropriate specialists if needed should be pursued if signs of these conditions are found.
2	Lifestyle modifications	Lifestyle modifications include weight management counseling with exercise and nutrition recommendations. Weight loss of 5-10% is the best supported modification. Other lifestyle modifications include counseling to: • Consider avoiding antiperspirant and using deodorant only, or switching to spray • Wash affected areas gently with fingers; do not scrub with washcloth or brush • Avoid overly tight clothing • Smoking/vaping cessation • NSAIDs or corticosteroids can be considered in short courses to reduce pain and inflammation • Avoid popping/draining new forming lesions ⁷
3	Topical therapy	 Topical clindamycin 1% solution may help to reduce inflammatory lesions and pustules Clean involved area with soap and water, dry, and apply the 1% clindamycin solution with fingertip 2x/day in skin areas subject to recurrent flares for 3 months Benzoyl peroxide 10% antiseptic wash must be used in conjunction with topical clindamycin to prevent Staph aureus resistance Other antiseptic washes that can be alternated daily with benzoyl peroxide include: Chlorhexidine gluconate 4% Shampoo containing zinc pyrithione 1%
4	Long-term oral antibiotics	 Long-term oral antibiotics have been shown to improve HS, although the mechanism is not definitively known. Patients who achieve satisfactory disease control may stop and then use zinc gluconate 50mg 2x/day for longer disease-free remission. a. Oral doxycycline 100mg 2x/day for 3-6 months (at least 3 months prior to assessing response). Strongly encourage patients to take this with a full meal to improve tolerability. Not recommended for pediatric patients under the age of 9. Refer younger patients with HS to dermatology sooner for management. b. Oral clindamycin 300mg 2x/day plus rifampin 300mg 2x/day for 12 weeks as second-line therapy if patients fail to respond to doxycycline.

#	Subject	Description
5	Antiandrogenic agents	 Some female patients have noted menstrual variation in their HS, indicating a role of hormones in HS. Antiandrogenic therapy in women seem to have a stronger response compared to antibiotic use. Antiandrogenic agents should NOT be given to pregnant women because of the risk for adverse effects on the fetus. Always conduct a pregnancy test before considering use of antiandrogenic agents. Oral contraceptive pills (OCP) improve clinical symptoms Ethinyl estradiol 50 mcg (cycled days 5 to 25) and cyproterone acetate 50mg (cycle days 5 to 14) for 6 months Ethinyl estradiol 50mcg and norgestrel 500mcg (cycle days 5 to 25) daily for 6 months Administration of combined OCPs containing ethinyl estradiol are key. Progesterone-only hormonal therapies can trigger or worsen HS, and it is recommended to switch to a different therapy if an HS patient is already on a progesterone-only agent. Spironolactone for HS associated with improvement in pain, lesions, and disease severity, especially for patients with PCOS. Start with 25mg/day and go up to 100mg/day for at least 3 months
6	Metformin	Insulin-resistance may contribute to HS, and metformin has shown benefit in HS along with modest weight loss for patients with obesity, particularly those with metabolic syndrome, PCOS or diabetes. 500mg initial dose 2x/day with food and titrate 500mg 1x/day x 1-2 weeks to minimize side effects, then increase to 500mg 2x/day for at least 3 months
7	Acute symptomatic lesions	 When patient has new forming lesion, counsel patient to intermittently apply warm compress over area for 10 minutes at a time throughout the day. This can improve symptoms of inflammation. If lesion starts to drain on its own, keep wound clean and wash gently with antiseptic wash. Cover the skin with petroleum jelly to avoid dressing from sticking to the wound, and clean/change dressing daily until wound heals. Adhesive tape should be avoided if possible, and instead an absorbent material should be held in place in a way that minimizes skin trauma, such as an elastic fishnet dressing. If lesion continues to be painful and inflamed, instruct patient to call doctor to discuss additional methods for treating acute symptomatic lesions. Additional interventions by dermatology: intralesional corticosteroid injections (triamcinolone 10mg/mL), punch debridement (partial unroofing) and topical resorcinol (topical 15% resorcinol).

Sources:

Children's National Hospital Dermatology Department

American Academy of Dermatology, North American clinical management guidelines for HS, https://doi.org/10.1016/j.jaad.2019.02.068 International Journal of Women's Dermatology, A concise clinician's guide to therapy for hidradenitis suppurativa, Nesbitt et al., doi: 10.1016/j. ijwd.2019.11.004

UpToDate, Hidradenitis Suppurativa: Management, Ingram, https://www.uptodate.com/contents/hidradenitis-suppurativa-management Liy-Wong C, Kim M, Kirkorian AY, et al. Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Crosssectional Study of 481 Pediatric Patients. JAMA Dermatol. Published online February 24, 2021. doi:10.1001/jamadermatol.2020.5435